Abstract: A bone cement paste containing a powder component comprising ?-tricalcium phosphate (?-TCP) particles having an average size greater than or equal to 9 ?m, and a liquid component comprising blood is disclosed. A method for preparation of the phosphocalcic cement composition is also disclosed.

Abstract: A bone cement paste containing a powder component comprising ?-tricalcium phosphate (?-TCP) particles having an average size greater than or equal to 9 ?m, and a liquid component comprising blood is disclosed. A method for preparation of the phosphocalcic cement composition is also disclosed.

Abstract: A method for promoting spine fusion inside intersomatic cages, comprising placing a fusion cage between two vertebral bodies, and injecting a bone cement paste inside said fusion cage, said bone cement paste containing a powder component comprising ?-tricalcium phosphate (?-TCP) particles having an average size greater than or equal to 9 ?m, and a liquid component comprising blood.

Abstract: A method for promoting spine fusion inside intersomatic cages, comprising placing a fusion cage between two vertebral bodies, and injecting a bone cement paste inside said fusion cage, said bone cement paste containing a powder component comprising ?-tricalcium phosphate (?-TCP) particles having an average size greater than or equal to 9 ?m, and a liquid component comprising blood.

Abstract: A bone cement paste containing a powder component comprising ?-tricalcium phosphate (?-TCP) particles having an average size greater than or equal to 9 ?m, and a liquid component comprising blood is disclosed. A method for preparation of the phosphocalcic cement composition is also disclosed.

Abstract: The present invention relates to a galliated calcium-phosphate biomaterial comprising a gallium-doped phosphocalcic compound of formula (I): Ca(10.5-1.5x)Gax(PO4)7??(I) wherein 0<x<1 and the salts, hydrates and mixtures thereof and/or a calcium deficient apatite structure with in particular a (Ca+Ga)/P molar ratio in the range of 1.3 to 1.67, and a gallium content up to 4.5% by weight. It also relates to processes of preparation of such materials and uses thereof, in particular as dental or bony implants. It further relates to a kit comprising a galliated calcium-phosphate biomaterial in combination with a fluid component. It finally relates to methods of use of the galliated calcium-phosphate biomaterial, notably for III) ions increase radio-opacity after bone implantation and can be released for inhibiting bone resorption.

Abstract: The present invention relates to a galliated calcium-phosphate biomaterial comprising a gallium-doped phosphocalcic compound of formula (I): Ca(005-1 5X)Gax(PO—O4)7, wherein 0<x<1 and the salts, hydrates and mixtures thereof and/or a calcium deficient apatite structure with in particular a (Ca+Ga)/P molar ratio in the range of 1.3 to 1.67, and a gallium content up to 4.5% by weight. It also relates to processes of preparation of such materials and uses thereof, in particular as dental or bony implants. It further relates to a kit comprising a galliated calcium-phosphate biomaterial in combination with a fluid component. It finally relates to methods of use of the galliated calcium-phosphate biomaterial, notably for III) ions increase radio-opacity after bone implantation and can be released for inhibiting bone resorption.

Abstract: The present invention relates to a galliated calcium-phosphate biomaterial comprising a gallium-doped phosphocalcic compound of formula (I): Ca(10.5?1.5x)Gax(PO4)7??(I) wherein 0<x<1 and the salts, hydrates and mixtures thereof and/or a calcium deficient apatite structure with in particular a (Ca+Ga)/P molar ratio in the range of 1.3 to 1.67, and a gallium content up to 4.5% by weight. It also relates to processes of preparation of such materials and uses thereof, in particular as dental or bony implants. It further relates to a kit comprising a galliated calcium-phosphate biomaterial in combination with a fluid component. It finally relates to methods of use of the galliated calcium-phosphate biomaterial, notably for III) ions increase radio-opacity after bone implantation and can be released for inhibiting bone resorption.